ALN-2232: Dedicated RNAi program for obesity & weight management (Phase 1 data expected H2 2026) $4.9-$5.3B projected 2026 revenue, fueling aggressive expansion in metabolic and cardiometabolic pipelines 10+ tissue types & 40+ clinical programs targeted by 2030 ~30% of revenues reinvested into R&D, accelerating next-generation metabolic innovation Reinforces obesity's emergence as a foundational pillar of future medicine ------------------------------------------------------------- Stay up to date with everything obesity through my newsletter Todays popular weight-loss drugs (like Wegovy or Zepbound) are GLP-1 agonists
Your GP can advise on the most appropriate option for your circumstances
These lumps aren't just a cosmetic issue
Its impact will depend not only on clinical efficacy, but also on whether health systems ensure access, affordability, and inclusive research
Your Lipoma Removal Consultation Lipoma consultations at Centre for Surgery take place at our Baker Street clinic in Marylebone
In fact, when researchers looked across 13 different GLP-1 studies, they found that females achieved more weight loss than males
